文献速递糖尿病性腺与生殖内分泌

胰岛素需求量下降与母体生物标志物及胎盘功能障碍的关联:妊娠期孕前糖尿病女性的前瞻性研究

The Association of Falling Insulin Requirements With Maternal Biomarkers and Placental Dysfunction: A Prospective Study of Women With Preexisting Diabetes in Pregnancy.
PubMed 文献 · Diabetes Care · 2017-08-10

多中心前瞻性队列研究纳入158例孕前糖尿病女性(1型41例,2型117例),32例在孕20周后总日剂量峰值下降≥15%定义为胰岛素需求量下降(FIR)。FIR与胎盘功能障碍复合结局(OR 4.38,95%CI 1.9-10.3;P<0.001)及子痫前期(OR 6.76,95%CI 2.7-16.7;P<0.001)风险升高相关,且在1型糖尿病中更常见(36.6% vs 14.5%;P=0.002)。

要点

  • 孕20周后胰岛素需求量较峰值下降≥15%与胎盘功能障碍复合结局风险升高相关(OR 4.38)。
  • FIR与子痫前期风险升高相关(OR 6.76),且在1型糖尿病女性中更常见(36.6% vs 14.5%)。
  • FIR女性在孕25、30、36周sFlt-1/PlGF比值显著更高,胎盘激素组间无差异。

核心结论

  • 本研究首次前瞻性将FIR与胎盘抗血管生成因子表达改变及子痫前期相关联。
  • FIR是孕前糖尿病女性中提示潜在胎盘功能障碍的重要临床征象,应提醒临床医生进一步检查。

研究设计与样本

  • 多中心前瞻性队列研究,纳入158例孕前糖尿病女性(1型糖尿病41例,2型糖尿病117例)。
  • 孕20周后总日剂量较峰值下降≥15%者定义为病例组(n=32)。
  • 主要结局为胎盘功能障碍临床标志物复合结局:子痫前期、小于胎龄儿(≤第5百分位)、死产、早产(<30周)及胎盘早剥。
  • 妊娠期间系列检测母体循环血管生成标志物(PlGF、sFlt-1)、胎盘激素(人胎盘催乳素、孕酮、肿瘤坏死因子-α)、HbA1c及肌酐。

主要发现

  • FIR≥15%与复合主要结局风险升高相关(OR 4.38,95%CI 1.9-10.3;P<0.001)。
  • FIR≥15%与子痫前期风险升高相关(OR 6.76,95%CI 2.7-16.7;P<0.001)。
  • FIR在1型糖尿病女性中更常见(36.6% vs 14.5%;P=0.002)。
  • FIR≥15%女性肌酐轻度升高,但HbA1c无差异。
  • FIR女性在孕25、30、36周sFlt-1/PlGF比值显著更高,该差异在发生子痫前期的亚组中维持;胎盘激素组间无差异。

临床怎么用

  • 作者认为,FIR是孕前糖尿病女性中应提醒临床医生检查潜在胎盘功能障碍的重要临床征象。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association of falling insulin requirements (FIR) among women with preexisting diabetes with adverse obstetric outcomes and maternal biomarkers longitudinally in pregnancy. RESEARCH DESIGN AND METHODS: A multicenter prospective cohort study of 158 women (41 with type 1 diabetes and 117 with type 2 diabetes) was conducted. Women with FIR of ≥15% from the peak total daily dose after 20 weeks' gestation were considered case subjects (n = 32). The primary outcome was a composite of clinical markers of placental dysfunction (preeclampsia, small for gestational age [≤5th centile], stillbirth, premature delivery [<30 weeks], and placental abruption). Maternal circulating angiogenic markers (placental growth factor [PlGF] and soluble fms-like tyrosine kinase 1 [sFlt-1]), placental hormones (human placental lactogen, progesterone, and tumor necrosis factor-α), HbA1c, and creatinine were studied serially during pregnancy. RESULTS: FIR ≥15% were associated with an increased risk of the composite primary outcome (odds ratio [OR] 4.38 [95% CI 1.9-10.3]; P < 0.001), preeclampsia (OR 6.76 [95% CI 2.7-16.7]; P < 0.001), and was more common among women with type 1 diabetes (36.6 vs. 14.5%; P = 0.002). Creatinine was modestly elevated among women with FIR ≥15%; however, there was no difference in HbA1c. The ratio of sFlt-1 to PlGF was significantly higher among women with FIR at 25, 30, and 36 weeks, with differences maintained in the subgroup that developed preeclampsia. There was no difference in placental hormones between the groups. CONCLUSIONS: This is the first prospective study to associate FIR with altered expression of placental antiangiogenic factors and preeclampsia. FIR are an important clinical sign, among women with preexisting diabetes, that should alert the clinician to investigate underlying placental dysfunction.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Padmanabhan S, Lee VW, Mclean M, et al. The Association of Falling Insulin Requirements With Maternal Biomarkers and Placental Dysfunction: A Prospective Study of Women With Preexisting Diabetes in Pregnancy. Diabetes Care. 2017. PMID: 28798085. doi:10.2337/dc17-0391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。